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Background: We investigated several adjuvants for their effects on the humoral immune response in both mice
and cattle using the central domain of congopain (C2), the major cysteine protease of Trypanosoma congolense, as
a model for developing a vaccine against animal trypanosomosis. The magnitude and sustainability of the immune
response against C2 and the occurrence of a booster effect of infection, an indirect measure of the presence of
memory cells, were determined by ELISA, while spectrofluorometry was used to determine and measure the
presence of enzyme-inhibiting antibodies.
Results: Mice immunized with recombinant C2 in TiterMaxTM, AdjuphosTM, purified saponin Quil ATM or GerbuTM
showed the best response according to the evaluation criteria and the latter three were chosen for the cattle
vaccination study. The cattle were challenged with T. congolense four and a half months after the last booster.
Cattle immunized with recombinant C2 in purified saponin Quil ATM showed the best antibody response according
to the measured parameters.
Conclusions: We identified purified saponin Quil ATM as a good adjuvant for immunizations with C2. The results
from this study will be useful in future attempts to develop an effective anti-disease vaccine against African
trypanosomosis.Background
Trypanosomosis is a chronic wasting disease afflicting
cattle and other livestock in sub-Saharan Africa and
other parts of the world [1] and is caused by tsetse fly-
transmitted protozoan parasites belonging to the genus
Trypanosoma. Chemotherapy and chemoprophylaxis
have not proved to be very effective against the disease
due to two main reasons:- the prohibitively high cost of
trypanocidal drugs to resource-poor farmers [2] and the
development of drug resistance [3]. Efforts to develop a
vaccine directed against the immunodominant variant
surface glycoprotein (VSG) have not been successful due
to antigenic variation [4]. Vaccination efforts have
shifted towards the characterization of invariant antigens
that are accessible to the specific antibodies such as gly-
cerophosphate-inositol anchor [5], flagellar pocket (FP)
fractions [6] and tubulin [7].* Correspondence: katereggaj@vetmed.mak.ac.ug
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reproduction in any medium, provided the orAn alternative approach based on an ‘anti-disease’ ra-
ther than an anti-parasite vaccine strategy was proposed
following observations that trypanotolerant African taur-
ine cattle, which have a natural ability to control tryp-
anosome infection [8], develop more prominent
antibody responses to congopain - the major cysteine
protease (CP) of T. congolense than trypanosusceptible
breeds [9]. It was hypothesized that congopain may
therefore play a role in pathology of the disease, and
antibody-mediated inhibition of this enzyme may con-
tribute to mechanisms of trypanotolerance [10]. It hence
constitutes a promising candidate vaccine in the sense
that immunization of trypanosusceptible cattle with ap-
propriate forms of cysteine proteases may confer a de-
gree of resistance to the disease [11,12].
The goal of vaccination is to stimulate a strong, pro-
tective and long lasting immune response to the admi-
nistered immunogen. To achieve these objectives, potent
adjuvants are required to make the antigen sufficiently
immunogenic to initiate a potent immune response [13].
While adjuvants were initially thought of as agentsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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new evidence has shown that adjuvants influence the
titer, isotype and avidity of antibody, and affect the prop-
erties of cell-mediated immunity [14]. Adjuvants can
therefore be used to improve the immune response to
vaccine antigens for several different purposes, i.e. in-
creasing the immunogenicity of weak antigens; enhan-
cing the speed and duration of the immune response;
decreasing the dose of antigen in the vaccine to reduce
costs or decreasing the number of immunizations [15].
This study was carried out within the framework of
the European Union-funded INCO-DEV Trypadvac2
project (PL003716), the overall objective of which is to
limit pathology associated with trypanosomal infections
through development of an anti-disease vaccine. We
investigated the effects of an array of adjuvants on the
immune response in mice, and selected the best three
adjuvants for a similar investigation in cattle using re-
combinant congopain (C2) [16] as a model antigen. The
general objective of the study was to find the best adju-
vant(s) giving an adequate response to be used in anti-
disease vaccine trials. The rationale behind using C2 as a
model lies in the fact that it has been shown to be poorly
immunogenic, is a highly conformational, compact pro-
tein and its protective epitopes are dimer-specific [16].
In our study, response to C2 was monitored using four
key parameters, namely 1/magnitude of the humoral im-
mune response to immunization, 2/sustainability of the
response after the last booster, 3/presence of enzyme-
inhibiting antibodies and 4/occurrence of a booster ef-
fect of infection, an indirect measure of the presence of
memory cells, whereby the re-exposure of the animals’
immune system to the immunizing antigen released dur-
ing infection triggers an activation of the specific im-
mune response.
We report here the detailed comparison of seven
adjuvants of various types in mice and three in cat-
tle, following the above parameters, leading to the
selection of saponin-based Quil A [17] for subse-
quent immunization/challenge experiments in the de-
velopment of an anti-disease vaccine against African
trypanosomosis.Methods
Materials
Congopain central domain (C2) was prepared as described
in [16]. The antigen, expressed in Pichia pastoris as a
recombinant antigen, was purified from the culture
medium using a combination of three phase partitioning
(TPP) [18] and ion-exchange and molecular exclusion
chromatography. The batch used for immunization was
freshly purified, and the dimeric conformation assessed
thoroughly before use [16].The adjuvants used in the study were; GERBU Adju-
vantTM type 100 #3100 [GERBU Biotechnik GmbH,
Gaiberg, Germany]; AdjuphosTM (aluminum phosphate)
batch 8987 [Brenntag Biosector, Frederikssund, Denmark];
AlhydrogelTM (aluminum hydroxide) batch 3666 [Brenntag
Biosector]; TiterMaxTM [Sigma-Aldrich Chemie GmBH,
Munich, Germany]; Freund’s complete adjuvant (FCA)
[Sigma-Aldrich Chemie GmBH]; purified saponin
Quil ATM batch L-77-238 [Brenntag Biosector] and
α2-macroglobulin (α2M). α2M was purified from bovine
plasma and complexed with recombinant C2 at a 1:1 molar
ratio as described in [19]. Freund’s incomplete adjuvant
(FIA) [Sigma-Aldrich Chemie GmBH] was used during the
booster immunizations for the FCA groups.
Swiss mice, aged 4–6 weeks at the start of the study,
were housed in the Laboratory Animal experimental fa-
cilities of the School of Veterinary Medicine of Makerere
University, Uganda, in cages containing 5 animals each.
Mice were fed on normal rodent pellets and water pro-
vided ad-libitum.
Trypanosome-free female Ankole cattle (aged 8–18 months)
were used in the cattle study. Sera from a number of
candidate animals for the experiment were screened
for any prior exposure to trypanosomal antigens
using standard ELISA [20]. In addition, ELISA was
performed with cattle sera on C2-coated microtiter
plates (Maxisorp, Nalge NUNC Int, Rochester, IL,
USA) to check for non-specific reactivity to C2. Sera
from trypanosome-infected cattle served as a positive
control. Only anti-C2 negative animals were selected
for the study. The cattle, initially acclimatized for 8 weeks,
were kept indoors for the duration of the experiment in the
fly-proof Large Animal Experimental Facilities of the
College of Veterinary Medicine, Animal. Resources and
Biosecurity of Makerere University, Uganda. They were
fed on hay and concentrate, with mineral and vitamin
supplements occasionally provided. Water was made
available ad-libitum. For both mouse and cattle experi-
ments, animal ethics clearance was obtained from the
Higher Degrees Committee of the College of Veterinary
Medicine, Animal Resources and Biosecurity of Makerere
University, Uganda.
The trypanosome stabilates used in the experiments
were obtained from the International Livestock Research
Institute (ILRI), Nairobi, Kenya. Trypanosoma congolense
IL3000 strain [21] was used in cattle and T. congolense
IL1180 parasites [22] in mice since IL3000 was deemed
too pathogenic for rodents [23].
Mice immunization, trypanosome challenge and blood-
sample collection
A total of 90 mice were randomly assigned to nine
groups of 10 mice each, 5 males and 5 females, kept sep-
arately. Seven groups were immunized with C2 in
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and a last group with PBS with neither adjuvant nor
antigen (negative control). The mice received an initial
immunization of 20 μg of C2 followed by two boosters
of 10 μg of C2 each, at monthly intervals. For GERBUTM,
TiterMaxTM and FCA the antigen and adjuvant were
prepared in a ratio of 1:1 (v/v), 100 μl per mouse,
thoroughly mixed/emulsified and administered sub-
cutaneously (SC) in two sites. For aluminum-based adju-
vants, 50 μl of antigen was mixed with 50 μl of adjuvant
suspension, corresponding to approximately 250 μg of
metallic aluminum per dose for AdjuphosTM and 500 μg
for AlhydrogelTM. For the mice immunized with Quil ATM,
20 μg of C2 was mixed with 20 μg of adjuvant using a
2 mg/ml stock in a 1:1 v/v ratio giving a final concentration
of adjuvant of 1 mg/ml, as recommended by the manufac-
turers, in a total volume of 100 μl per dose. The α2M-C2
complexes corresponding to 20 μg of C2 were diluted to
100 μl per mouse in PBS and injected as described
previously [19]. Adjuvants were used at all booster
immunizations but FIA was used for the boosters for
the FCA group.
The mice were bled weekly from the tail (1–1.5 ml of
blood per group) for the first 3 months and later once a
month for the next 6 months to determine the magni-
tude and sustainability of the antibody response respect-
ively. Blood samples from individual mice were pooled
according to the different experimental groups to ensure
sufficient serum volumes for analyses and to determine
the average response of all the mice in each group,
rather than individual animals’ responses. The samples
were centrifuged and sera were collected and stored at
−20°C until further analysis. Large amounts of sera
(1.5-2 ml per group) were also collected at the time
of the hypothetical peak of the response i.e. 2 weeks
post last booster and used for immunoglobulin puri-
fication for enzyme inhibition assay purposes. Six
months after the last booster, mice were challenged
with T. congolense (103 parasites per mouse adminis-
tered intra-peritoneally). For the infection, infected
mouse blood diluted in PBS was used. The infected
blood was obtained from Swiss mice which had earlier
been infected with 103T. congolense IL1180 parasites
per mouse and their parasitaemia monitored daily. The
trypanosome challenge experiment was aimed at deter-
mining the presence of a ‘booster effect’ of infection on
the immune response (memory) in the immunized mice
when compared with the control mice that were not
immunized but infected with parasites.
Cattle immunization, challenge and sample collection
Twenty cattle were randomly assigned to five groups of
4 animals each. Three groups were immunized with C2
in combination with one of 3 different adjuvants(GERBUTM, AdjuphosTM, Quil ATM). Positive and negative
control groups were immunized with C2 in FCA and C2
in PBS without adjuvant respectively. FCA was used as
positive control since its ability to enhance the immune
response in cattle was previously proven (Boulangé,
unpublished observation) and for this group, FIA was
used during the boosters. Cattle were initially immu-
nized with 100 μg of C2 per animal, followed by two
booster immunizations (50 μg per animal), done at two-
week intervals after the initial immunization. The antigen/
adjuvant mixtures were prepared as a 1:1 (v/v) ratio in a
total volume of 3 ml per dose, directly for FCA, GERBUTM
and AdjuphosTM (for the latter giving a 7.35 mg metallic
aluminum per dose), and using a 2 mg/ml solution for
Quil ATM, i.e. 1 mg/ml, or 3 mg per dose. Animals were
injected SC in the dew-lap, at two sites.
Blood from the individual animals (10 ml) was col-
lected from the jugular vein at weekly intervals for the
first 3 months of the experiment using serum separator
tubes containing clot activator and serum separator gel
(YanvacTM, Xiamen, Fujian, China). Sera were separated
for ELISA purposes. A larger bleed (25 ml per cattle)
was done 15 days post last booster, the alleged peak of
response, for purification of IgGs for enzyme inhibition
assay purposes. Thereafter blood collection was done
once a month for 4½months to monitor the sustainabil-
ity of the antibody response. The sera were stored at
−20°C until further analysis.
Four and a half months after the last booster, animals
were infected with T. congolense IL3000 (103 parasites
per animal), intra-dermally using an intra-dermal syr-
inge. Trypanosomes originated from fresh, PBS-diluted
infected mouse blood. After challenge, the animals were
monitored daily to determine the pre-patent period.
Thereafter blood samples were also collected from the
jugular vein twice a week in EDTA tubes to determine
PCV (using the hematocrit method) and parasitaemia
using wet smears or the hematocrit centrifugation-buffy
coat technique [24]. Sera were collected once a week
from one of the two blood samples to monitor the dy-
namics of the immune response and determine presence
of a ‘booster effect of infection’. The degree of effective-
ness of the adaptive immune response in providing pro-
tective immunity to infection was also assessed through
monitoring PCV values twice a week. All the animals
were treated with diminazene aceturate (VeribenW,
CEVA Santé Animale, Libourne, France) 8 weeks post-
infection. Post-treatment serum samples were collected
2 weeks later.
Determination of anti-C2 antibody response by ELISA
The magnitude and sustainability of the immune re-
sponse was determined by ELISA. Wells of ELISA plates
(Corning-Costar, Lowell, MA, USA) were coated with
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9.6 and incubated overnight at 4°C. After discarding the
contents of the wells, non specific binding sites were
blocked with 100 μl of 0.5% (w/v) BSA (Fraction V,
Sigma-Aldrich) in PBS by incubation at 37°C for 1 h.
Sera, 1:100 dilution in 0.5% (w/v) BSA in PBS, were
added and incubated for 2 h at 37°C. The wells were
rinsed with PBS (pH 7.4) and washed twice with PBS
containing 0.05% (v/v) Tween-20. For mouse sera,
100 μl of rabbit anti-mouse horse radish peroxidase
(HRPO)-conjugated IgG (Sigma-Aldrich #A9044), diluted
1:5,000 in 0.5% (w/v) BSA in PBS, was used. For cattle
sera, 100 μl of rabbit anti-bovine HRPO-conjugated IgG
(Sigma-Aldrich #A5295) at a 1:20,000 dilution in 0.5%
(w/v) BSA in PBS was added to each well and incu-
bated for 1 h at 37°C. Substrate, 100 μl of 5 mM
ortho-phenylenediamine (OPD) in 50 mM citrate-
phosphate buffer (pH 5.0) containing 0.04% H2O2, was
added after the washing step. Plates were incubated
for 10–15 min at 25°C. The reaction was stopped
with 100 μl of 3 N H2SO4 and optical densities (ODs)
were determined at 492 nm using an ELISA reader
(FinstrumentsTM Microplate Reader, MTX Lab Systems,
Inc, Vienna, VA, USA).IgG purification
IgG was purified from mouse sera by using Protein
A-Sepharose (SigmaAldrich). The pH of the serum
was adjusted to 8.0 by mixing with 1/10th volume 1 M
Tris–HCl buffer, pH 8 before loading on the Protein
A-Sepharose. After washing the column with 10 col-
umn volumes of 100 mM Tris–HCl buffer (pH 8.0),
bound antibody was eluted with 100 mM glycine-HCl
buffer, pH 3.0. The eluate was collected in 1 ml frac-
tions containing 100 μl of 1 M Tris–HCl buffer, pH
8.5 and mixed gently to neutralize the pH. The IgG
containing fractions were identified by measuring the
absorbance at 280 nm.
IgG was purified from cattle sera by precipitation
using polyethylene glycol (PEG) Mr 6000 [25]. Sera from
the different animals in each group (according to adju-
vant), taken 2 weeks post-last booster were pooled intoTable 1 Computation of percent inhibition of C2 activity
IgG conc.
[μg/ml]






The slopes of the linear plots for the residual C2 activity were determined in a spec
inhibition of C2 activity was determined using the formula:Percentinhibitionof C2 ¼
Immune IgGs were obtained from mice or cattle immunized with C2 with adjuvant
immunization. The table shows the computation of percent inhibition of C2 activity15 ml tubes. One volume of cattle serum was diluted
with two volumes of borate buffered saline, pH 8.6
(composition - 2.16 g boric acid, 2.19 g NaCl, 0.7 g
NaOH and 0.62 ml of 37% (v/v) HCl dissolved in 950 ml
of distilled H2O). Solid PEG (Mr 6000) was added to the
diluted serum to 14% (w/v) and dissolved with constant
gentle stirring. The mixture was centrifuged (12000 × g;
10 min; 25°C) and the pellet redissolved in the original
serum volume, using 100 mM Na2PO4 buffer, pH 7.6,
containing 0.02% (w/v) NaN3. PEG was once again
added to 14% (w/v), dissolved with stirring and centri-
fuged (12000 × g; 10 min; 25°C). The resulting pellet
was re-dissolved in half the original serum volume using
100 mM Na2PO4 buffer, pH 7.6 containing 60% (v/v)
glycerol and stored at −20°C until further analysis. The
IgG concentrations were estimated using an extinction
coefficient of
P280nm
1mg=ml ¼ 1:43 ð26Þ.Inhibition of C2 activity
The in-vitro inhibition of C2 activity by purified IgGs
from mice and cattle was assessed using assays for the
hydrolysis of a fluorogenic peptide substrate. Ten ng of
active C2 (determined by active site titration with E-64)
[27] diluted in 75 μl of 0.1% (v/v) Brij-35 was mixed with
75 μl of the different IgG solutions diluted in C2 assay
buffer (100 mM Bis-Tris buffer, pH 6.4, 4 mM Na2EDTA
and 0.02% (w/v) NaN3) without dithiothreitol (DTT).
The inhibition assay was performed at three different
dilutions of IgG (i.e. 250 μg/ml, 125 μg/ml and 62.5 μg/
ml for mouse IgGs [final amount of 6.25, 3.125, and
1.56 μg per well respectively] and 1000 μg/ml, 500 μg/ml
and 250 μg/ml for cattle IgGs [final amount of 25, 12.5,
and 6.25 μg per well respectively]) collected 2 weeks after
the last booster immunisation. The mixtures (in micro-
fuge tubes) were incubated overnight at 4°C. A 50 μl ali-
quot from the C2-IgG mixture was added per well of
Fluoronunc Maxisorp 96-well plates (eBioScience, San
Diego, CA, USA), followedbyadditionof25μl of assaybuf-
fer containing 8 mM DTTand activated for 1 min at 37°C.
Thedipeptide fluorogenic substrateZ-Phenylalanyl-Argin-
ine-7-Amino-4-methyl coumarin (25 μl of 20 μMper well)
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while non-immune IgGs were obtained from mice or cattle before
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Figure 1 ELISA of anti-C2 antibody response of mice
immunized with C2 in different adjuvants. Mice were initially
immunized SC with 20 μg of C2 in AdjuphosTM GERBUTM,
AlhydrogelTM, TiterMaxTM, FCA, Quil ATM or α2M adjuvants. The first and
second booster immunizations (10 μg each) were done at 4 and
8 weeks post initial immunization respectively, indicated by arrows on
x-axis. ELISA plates were coated with overnight with C2 at 4°C. OPD
was used as substrate and absorbances were read at 492 nm. Each
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GmbH, Offenburg, Germany) using excitation at 360 nm
and emission at 460 nm. The slopes of the linear activity









The Student’s t test was used to determine statistically
significant differences in ODs or PCV between any two




Figure 2 ELISA of anti-C2 response of mice challenged with
T. congolense. Six months after the last booster, all the mice were
challenged with T. congolense IL1180 (103 parasites per mouse)
administered intra-peritoneally. Day 0 was the day of infection. Post
challenge antibody response was evaluated ELISA using sera
collected just before challenge (week 0), and at weeks 2 and
4 post-challenge.Results
Anti-C2 response in mice
To assess the anti-C2 response in mice, OD was deter-
mined instead of titer as titer determination would re-
quire large volumes of sera and running a large number
of assays. The objective of the mice experiment was to
provide a simple evaluation of the anti-C2 response indifferent adjuvant groups in order to choose the best
adjuvants for the cattle study. The magnitude and sus-
tainability of the response, presence of enzyme inhibiting
antibodies post-immunization and occurrence of a
booster effect of infection following challenge were
evaluated.
Generally, peak antibody responses were observed
around weeks 6 and 10 post initial immunization i.e.
2 weeks after the first and second booster immuniza-
tions respectively (Figure 1). The duration of the anti-
body response was evaluated by comparing the
magnitude of response after week 10. Mice immunized
with C2 combined with either QuilTM, AdjuphosTM,
TiterMaxTM, FCA and GERBUTM adjuvants showed the
best results in terms of magnitude and duration of
response.
Figure 2 shows that there was a booster effect on the
antibody response following infection of mice immu-
nized with C2 in TiterMaxTM, Quil ATM, AdjuphosTM and
GERBUTM adjuvants. The booster effect was however, ra-
ther short lived for Quil ATM and GERBUTM. The pres-
ence of a booster effect of infection could not be
determined for the groups immunized with α2M or FCA
because a number of animals in these groups had died
during the course of the experiment, such that the
remaining numbers did not constitute a statistically rep-
resentative sample.
Purified IgGs from sera of TiterMaxTM, GERBUTM or
AdjuphosTM mice groups showed the highest levels of in-
hibition of C2 activity in vitro (Figure 3). The highest in-
hibition (66%) was obtained with IgGs purified from sera
of mice immunized with C2 with TiterMaxTM adjuvant at
an IgG concentration of 250 μg/ml; followed by
Figure 3 Percent inhibition of C2 activity by IgGs purified from sera of immunized mice. Inhibition assays were used to assess the ability of
immune IgGs to inhibit C2 activity in-vitro. IgGs were purified by affinity chromatography on Protein A-Sepharose, from serum collected 2 weeks
post-last booster. The assays were performed at three different concentrations of IgG i.e. 250, 125 and 62.5 μg/ml (final amount of 6.25, 3.125, and
1.56 μg per well respectively) and with 3.3 ng C2 per well. The C2-IgG mixtures were incubated overnight at 4°C. Residual C2 activity was
measured after activation with 8 mM DTT. The fluorogenic substrate used was 20 μM Z-Phe-Arg-AMC and the fluorescence recorded (excitation
360 nm and emission 460 nm). The percent inhibition of C2 activity was determined from the slopes of the linear plots of residual C2 activity.
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from the GERBUTM group showed the greatest degree of
inhibition when the IgG concentration was halved to
125 μg/ml (i.e. 44% inhibition). At a lower IgG concen-
tration i.e. 62.5 μg/ml, Adjuphos appears to be margin-
ally the best (Figure 3).
In summary, TiterMaxTM, AdjuphosTM, GERBUTM and
Quil ATM were deemed the ‘best’ adjuvants in the mice
experiment and the latter three were selected for the cat-
tle study (see below). The GERBUTM and AdjuphosTM

















Figure 4 ELISA of anti-C2 response in cattle after immunization.
Cattle were each immunized SC with 100 μg of C2 in GERBUTM,
AdjuphosTM, Quil ATM or FCA. A control group was immunized with C2
alone. Two booster immunizations (50 μg per animal) were done at 2
weekly intervals after the initial immunization as indicated by the arrows
on the x-axis. Reactivity towards C2 was monitored by ELISA.effect of infection on antibody levels and a high level of
inhibition of C2 activity in vitro. The Quil ATM group
showed a high peak response and a booster effect of
infection. Despite the good results showed by the
TiterMax group (good response, booster effect of infec-
tion and C2 inhibition), this adjuvant was not chosen
for the cattle study since it was very expensive and not
ideal for use in a cost-friendly anti-disease vaccine.
Anti-C2 response in cattle
Like in the mouse experiment, the main parameters



















Figure 5 ELISA of anti-C2 antibodies produced in cattle post
infection. Four and a half months after the last immunization
booster, all the cattle were infected intra-dermally with T. congolense
IL3000 (103 parasites per animal). The pre-patent period was 9–11 days.
The arrows show the ‘booster effect’ of infection around 2 weeks post
















Adjuvants 250 500 1000 µg/ml
Figure 6 Percent inhibition of C2 activity by cattle IgGs. Inhibition assays to assess the ability of immune IgGs to inhibit C2 activity in-vitro
were performed at IgG conc. of 1000, 500 and 250 μg/ml (25, 12.5, and 6.25 μg per well respectively). The amount of C2 used in the assay was
1.65 ng active enzyme per well. The C2-IgG mixtures were incubated overnight at 4°C and residual C2 activity was measured after activation with
8 mM DTT. The fluorogenic substrate used was 20 μM Z-Phe-Arg-AMC and the fluorescence recorded (excitation 360 nm and emission 460 nm).
Percent inhibition of C2 activity was determined from slopes of the linear plots of residual C2 activity.
















Figure 7 Mean PCV of experimental cattle following challenge
with T. congolense. Following challenge with T. congolense IL3000
parasites, PCV was determined weekly using the hematocrit method,
for 10 weeks. Animals were treated at week 8 (day 56), and a last
sample collected 2 weeks later.
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in-vitro and a booster effect of infection on antibody
levels. Two peaks in the immune response were
observed i.e. around 2 weeks post first booster and
2–4 weeks post second booster (Figure 4). Cattle
immunized with C2 in Quil ATM showed the best antibody
response. This was followed by cattle immunized with C2
in FCA, and C2 in GERBU AdjuvantTM (Figure 4). The dif-
ferences between FCA and Quil ATM or GERBUTM and
Quil A groups were not significant (p> 0.05). How-
ever there was a significantly higher response (by OD)
for the Quil ATM group when compared with the Adju-
phosTM group (p< 0.05). The antibody response was best
sustained at high levels in animals immunized with C2 in
Quil ATM (Figure 4).
The pre-patent period for the appearance of parasites
in circulation after challenge was 9–11 days. Following
infection, the antibody response (as measured by OD)
remained highest for animals immunized with C2 in
Quil ATM, AdjuphosTM or GERBUTM adjuvants (Figure 5).
However the ODs obtained post-challenge for animals
immunized with C2 in FCA were not significantly differ-
ent from those obtained for C2 alone (p> 0.05) indicat-
ing that the immune response for this group had waned.
A short-lived booster effect of infection was visible with
GERBUTM and Quil ATM groups around week 3 post
challenge (Figure 5), corresponding to 10–12 days
after the appearance of parasites in circulating blood.
There was also an increased response in all the cattle
groups after diminazine treatment probably due to
an antibody response to the release of antigens from
the dead trypanosomes.
The in-vitro C2 inhibition assays showed that IgGs
obtained from the Quil ATM, FCA, GerbuTM and Adju-
phosTM groups of cattle all showed high inhibition of theactivity of C2 (Figure 6), in the range of 60% to 70% in-
hibition. However at lower concentration of IgGs, Quil
ATM showed the highest inhibition of C2 activity, with up
to 40% inhibition at an IgG concentration of 250 μg/ml
(6.25 μg per well). Almost no inhibitory effect was
observed on C2 activity for the group immunized with
C2 alone. As shown in Figure 6, C2 inhibition increased
with IgG concentration.
In addition to the four key antibody parameters, PCV
was determined to evaluate the degree of protection
offered by the immunization. As shown in Figure 7,
PCV was highest for animals immunized with C2 in
Quil ATM (which also showed the highest antibody re-
sponse and enzyme inhibition) and least for animals
Kateregga et al. BMC Veterinary Research 2012, 8:63 Page 8 of 10
http://www.biomedcentral.com/1746-6148/8/63immunized with C2 alone, which showed the lowest
antibody response. This indicates that antibodies pro-
duced following immunization with C2 in adjuvant
could be more effective in alleviation of pathogenic
effects like anaemia. There were no parasitaemia differ-
ences between groups. However, we did not consider
parasitaemia a key parameter for choice of best adjuvant
given the ‘antidisease vaccine’ context of the study.
In summary, cattle in the Quil ATM, FCA and GERBUTM
groups showed the highest antibody response. A short
lived ‘booster effect of infection’ was observed in the
GERBUTM and Quil ATM groups while the highest level of
in-vitro inhibition of C2 activity was observed for the
IgGs from the Quil ATM group.
Discussion
The purpose of this study was to find the best adjuvant
(s) giving an adequate antibody response to be used in
anti-disease vaccine trials against African trypanosomo-
sis. The ‘best’ adjuvant was chosen based on the magni-
tude and sustainability of the antibody response,
presence of C2 inhibiting antibodies and a ‘booster effect
of infection’ but the cost factor, in case of later up-scal-
ing could not be neglected. Purified recombinant C2 was
used as the model for this study and its dimeric con-
formation was assessed thoroughly before use [16]. Re-
cent studies show that C2 protective epitopes seem to
be dimer associated [16], hence it is important that the
adjuvant preserve the conformation of the epitopes i.e.
the adjuvant should ideally have a neutral pH and not
denature the immunogen.
Quil ATM, a saponin-based adjuvant, was the best adju-
vant when the above mentioned parameters were con-
sidered as well as ease of mixing with the antigen prior
to immunization. Quil ATM is purified from a bark extract
of Quillaja saponaria Molina, a tree native to the Andes
region [13]. It consists of a triterpenoid aglycone to
which a.o. one or more sugar chains are attached [28].
Saponin-based adjuvants have the ability to enhance
antibody production as well as stimulate the cell
mediated immune system. They also have the advantage
that only a low dose is needed for adjuvant activity [29].
Saponins reportedly induce production of cytokines such
as interleukins and interferons that might mediate their
immunostimulant effects [13]. It is currently unknown if
the adjuvant effect of saponins is related to pore forma-
tion, which may allow antigens to gain access to the en-
dogenous pathway of antigens presentation, promoting
cytotoxic T-lymphocyte response [30]. Other studies also
suggest that Quillaja saponin has mitogenic activity and
induces T and B- cell proliferation [31].
Animals that received C2 with FCA produced an anti-
body response in both mice and cattle. Composed of
mineral oil, surfactant and mycobacteria, FCA hasalways been considered to be one of the most effective
adjuvants. However, in the cattle experiment, the re-
sponse waned after some time, such that ODs obtained
in ELISA measuring antibody levels post infection were
not significantly different from those obtained for the C2
alone group (p> 0.05). Low PCV was observed for the
cattle FCA group, indicating that antibodies produced
with FCA were clearly not protective. Since C2 contains
highly conformational epitopes it is not unlikely that ex-
posure to the lipophilic environment of the oil emulsion
induced conformational changes of C2 and subsequent
reduction of immunogenicity with time and this could
explain why there was no protection and no booster ef-
fect post-infection.
GERBUTM owes its adjuvant effect to the solid ultrafil-
trable particles of slowly biodegradable lipids (respon-
sible for depot effect) and the synergistic action of
N-acetyl-glucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglu-
tamine, a glycopeptide in the cell wall of Lactobacillus
bulgaricus. Both mice and cattle immunized with C2 in
GERBUTM showed a good antibody response. In cattle, the
response was significantly higher than for the FCA group
post challenge (p< 0.05).
Comparative studies in humans and animals have
shown that aluminum is a weak adjuvant for antibody
induction against small sized recombinant protein
vaccines [32]. In the present study however, AdjuphosTM
and AlhydrogelTM- administered groups showed good anti-
body responses in mice. Furthermore, the mouse group
administered with Adjuphos showed a booster effect of in-
fection. Animals in the Adjuphos-administered group
produced a significantly higher response (p< 0.05)
than those in the Alhydrogel group possibly because
the antigen could, for some reason have had a
higher binding to the phosphate than to the hydrox-
ide form.
Partial protection was observed in cattle immunized
with C2 in Quil ATM and in GERBUTM. The high level of
inhibition of in-vitro C2 activity by IgGs from cattle
immunized with C2 in Quil ATM or GERBUTM is an indi-
cator of the beneficial effect of these adjuvants in stimu-
lating the production of protective antibodies.
Antibodies that show anti-C2 activity in-vitro may have
the ability to inhibit the deleterious effects of circulating
congopain in-vivo such as immunosuppression, which
may aid in reducing the pathological effects of trypano-
somosis [12]. There was however no correlation between
the C2 inhibition activity and capacity to prevent a de-
crease in PCV for the adjuvant groups.
Although this study evaluated the anti-C2 response
using antibody parameters, the safety of the adjuvants is
also an important parameter to consider. In our study,
no adverse effects were observed for most of the adju-
vants, a notable exception is the mice immunized with
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challenge with trypanosomes. In cattle, one of the ani-
mals in the group that was immunized with FCA
showed an inflammatory response with formation of an
open necrotic wound. Two other animals in this group
showed painful swellings lasting several days. Further-
more, immunization parameters can also affect response
i.e. adjuvant and antigen dose, route and schedule of
immunization.
Conclusions
We have established that the use of purified saponin
Quil ATM enables the induction of a strong, sustained
antibody response against congopain (C2) in cattle. This
antibody response is also partially protective, purport-
edly due to the anti- congopain antibodies produced by
the immunized animals, which inhibit congopain activ-
ity. This investigation shows that use of a recombinant
antigen representative of the type of molecules that is to
be utilized in the design of a multicomponent anti-dis-
ease vaccine (typically active enzymes), enabled the iden-
tification of the most suitable adjuvant for this type of
study. This will make it possible to conduct vaccine
trials devoid of the artifacts associated with an inad-
equate immune response, to focus solely on the effects
of the studied antigens. It is hoped that it will serve as a
stepping stone to allow the development of an effective
anti-disease vaccine against African trypanosomosis.
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